Charles River Laboratories Intl. Inc (CRL) Shares Bought by MetLife Investment Advisors LLC

Share on StockTwits

MetLife Investment Advisors LLC increased its holdings in shares of Charles River Laboratories Intl. Inc (NYSE:CRL) by 1.7% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 30,113 shares of the medical research company’s stock after buying an additional 515 shares during the period. MetLife Investment Advisors LLC owned 0.06% of Charles River Laboratories Intl. worth $3,380,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. BlackRock Inc. boosted its holdings in shares of Charles River Laboratories Intl. by 7.0% in the second quarter. BlackRock Inc. now owns 4,446,965 shares of the medical research company’s stock valued at $499,216,000 after buying an additional 292,685 shares during the period. Assenagon Asset Management S.A. boosted its holdings in Charles River Laboratories Intl. by 99.1% during the second quarter. Assenagon Asset Management S.A. now owns 261,857 shares of the medical research company’s stock worth $29,396,000 after purchasing an additional 130,325 shares during the last quarter. Schwab Charles Investment Management Inc. boosted its holdings in Charles River Laboratories Intl. by 26.7% during the second quarter. Schwab Charles Investment Management Inc. now owns 382,582 shares of the medical research company’s stock worth $42,949,000 after purchasing an additional 80,519 shares during the last quarter. Massachusetts Financial Services Co. MA boosted its holdings in Charles River Laboratories Intl. by 64.7% during the second quarter. Massachusetts Financial Services Co. MA now owns 202,716 shares of the medical research company’s stock worth $22,757,000 after purchasing an additional 79,619 shares during the last quarter. Finally, Wells Fargo & Company MN boosted its holdings in Charles River Laboratories Intl. by 5.4% during the second quarter. Wells Fargo & Company MN now owns 1,316,635 shares of the medical research company’s stock worth $147,806,000 after purchasing an additional 67,439 shares during the last quarter. Hedge funds and other institutional investors own 97.78% of the company’s stock.

Several analysts have issued reports on CRL shares. UBS Group started coverage on shares of Charles River Laboratories Intl. in a research report on Tuesday. They set a “neutral” rating and a $140.00 price target on the stock. Credit Suisse Group upped their price target on shares of Charles River Laboratories Intl. from $121.00 to $128.00 and gave the stock a “neutral” rating in a research report on Tuesday, September 25th. Robert W. Baird upped their price target on shares of Charles River Laboratories Intl. from $133.00 to $141.00 and gave the stock an “outperform” rating in a research report on Monday, September 17th. Morgan Stanley increased their price objective on shares of Charles River Laboratories Intl. from $102.00 to $112.00 and gave the company a “hold” rating in a research report on Tuesday, September 11th. Finally, ValuEngine raised shares of Charles River Laboratories Intl. from a “hold” rating to a “buy” rating in a research report on Tuesday, September 11th. Seven equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $128.50.

In related news, COO Davide Molho sold 11,600 shares of the firm’s stock in a transaction that occurred on Monday, July 23rd. The shares were sold at an average price of $125.00, for a total value of $1,450,000.00. Following the completion of the transaction, the chief operating officer now owns 22,079 shares in the company, valued at approximately $2,759,875. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Deborah Turner Kochevar sold 4,066 shares of the firm’s stock in a transaction that occurred on Tuesday, September 4th. The shares were sold at an average price of $123.66, for a total transaction of $502,801.56. Following the completion of the transaction, the director now owns 10,190 shares of the company’s stock, valued at approximately $1,260,095.40. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 32,019 shares of company stock worth $3,914,826. 2.10% of the stock is currently owned by corporate insiders.

Shares of CRL traded up $2.12 during mid-day trading on Friday, reaching $122.99. The company had a trading volume of 510,207 shares, compared to its average volume of 374,756. Charles River Laboratories Intl. Inc has a 1-year low of $96.70 and a 1-year high of $135.90. The company has a current ratio of 1.72, a quick ratio of 1.48 and a debt-to-equity ratio of 1.52. The company has a market cap of $6.46 billion, a P/E ratio of 23.34, a PEG ratio of 1.69 and a beta of 0.65.

Charles River Laboratories Intl. (NYSE:CRL) last posted its quarterly earnings results on Wednesday, August 8th. The medical research company reported $1.62 earnings per share for the quarter, beating analysts’ consensus estimates of $1.46 by $0.16. Charles River Laboratories Intl. had a net margin of 6.38% and a return on equity of 25.26%. The company had revenue of $585.30 million for the quarter, compared to the consensus estimate of $570.65 million. During the same period last year, the company posted $1.29 EPS. The firm’s quarterly revenue was up 24.8% compared to the same quarter last year. On average, equities analysts forecast that Charles River Laboratories Intl. Inc will post 5.91 EPS for the current year.

Charles River Laboratories Intl. Profile

Charles River Laboratories International, Inc, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).

Read More: What is a conference call?

Institutional Ownership by Quarter for Charles River Laboratories Intl. (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.